Last updated 8 days ago
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)
720 patients around the world
Available in United States, Chile, Argentina, Colombia, Brazil
Merck Sharp & Dohme LLC
14Research sites
720Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Non-Hodgkin Lymphoma
Small lymphocytic lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Hospital Británico de Buenos Aires - CABA
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Hospital Alemán
Recruiting
Sanatorio Parque - Rosario
Recruiting
Centro Médico Fleischer
Recruiting
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
Recruiting
Biocenter
Recruiting
IC La Serena Research - La Serena
Recruiting
StudyBELLWAVE-010
SponsorMerck Sharp & Dohme LLC
Conditions
Chronic lymphocytic leukemiaSmall lymphocytic lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05947851
